Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Jyothy Laboratories Limited's net profit margin of 12.8% in FY2025 reflects moderate profitability, with operating margin at 17.2% and gross margin at 51.1%.
In FY 2025, Jyothy Laboratories Limited posted a gross margin of 51.1%, an operating margin of 17.2%, a net margin of 12.8%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Jyothy Laboratories Limited's revenue grew 3.3% to 29.03B and net profit grew 0.3% to 3.70B YoY in FY2025, indicating modest business momentum.
In FY 2025, Jyothy Laboratories Limited's revenue grew by 3.3% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Jyothy Laboratories Limited's ROE of 18.1% in FY2025 indicates good shareholder returns.
In FY 2025, Jyothy Laboratories Limited reported an ROE of 18.1%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Jyothy Laboratories Limited's FCF/NI ratio of 0.68x in FY2025 indicates FCF trailing profits — heavy capex or working capital needs may be a factor.
In FY 2025, Jyothy Laboratories Limited's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Jyothy Laboratories Limited's OCF/NI ratio of 0.84x in FY2025 indicates reasonable cash conversion from operations.
In FY 2025, Jyothy Laboratories Limited's operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Jyothy Laboratories Limited's current ratio of 2.76x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Jyothy Laboratories Limited reported a current ratio of 2.76. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Jyothy Laboratories Limited's interest coverage ratio of 84.2x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Jyothy Laboratories Limited reported an interest coverage ratio of 84.2x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Jyothy Laboratories Limited's debt-to-equity ratio of 0.03x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Jyothy Laboratories Limited reported a debt-to-equity ratio of 0.03. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Jyothy Laboratories Limited's debt increased 21.2% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Jyothy Laboratories Limited's total debt increased by 21.2% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Jyothy Laboratories Limited's diluted shares decreased 0.1% YoY in FY2025, indicating shareholder-friendly buybacks.
Over 2 years (FY2024–FY2025), diluted shares decreased 0.1% from 367.26M to 367.05M, reflecting long-term shareholder value creation.
In FY 2025, Jyothy Laboratories Limited's diluted shares decreased by 0.1% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025